NCT06296563View on ClinicalTrials.gov

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2029

Conditions
Intrahepatic Cholangiocarcinoma
Interventions
PROCEDURE

HAIC

FOLFOX-hepatic artery infusion for 2 times.

DRUG

Adebrelimab

Adebrelimab 1200mg, ivgtt, d1, q3w,up to one year of use at most.

DRUG

Apatinib

Apatinib 250mg, po, qd,q3w,up to one year of use at most.

Trial Locations (1)

250117

RECRUITING

Shandong Cancer Hospital and Institute, Jinan

All Listed Sponsors
lead

Lei ZHAO

OTHER